Joshua Belkar - Check Cap Vice President - Operations
| CHEK Stock | USD 0.81 0.01 1.25% |
President
Mr. Joshua Belkar was appointed as Vice President of Operations of the company, effective June 16, 2019. Mr. Belkar brings to the CheckCap team extensive leadership experience in the large volume manufacturing of capsulebased products at Medtronic and its subsidiaries, notably Covidien. Prior to joining CheckCap, Mr. Belkar served as Vice President of Operations and Global Services at Mazor Robotics Ltd., which was recently acquired by Medtronic Plc. Prior to Mazor Robotics, Mr. Belkar served in various executive roles at Medtronic, including Director of Operations, Vice President of Manufacturing and Operations and Director of Production. Before joining Medtronic Plc., Mr. Belkar served as Manager of Operations at Elscint Medical Systems Ltd since 2019.
| Age | 55 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Address | Check-Cap Building, Isfiya, Israel, 3009000 |
| Phone | 972 4 830 3401 |
| Web | https://www.check-cap.com |
Check Cap Management Efficiency
The company has return on total asset (ROA) of (0.3169) % which means that it has lost $0.3169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5406) %, meaning that it created substantial loss on money invested by shareholders. Check Cap's management efficiency ratios could be used to measure how well Check Cap manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.74. The value of Return On Capital Employed is expected to slide to -0.85. At this time, Check Cap's Total Current Liabilities is quite stable compared to the past year. Change To Liabilities is expected to rise to about 239 K this year, although the value of Liabilities And Stockholders Equity will most likely fall to about 20.9 M.Similar Executives
| Found 8 records | PRESIDENT Age | ||
| Steven PharmD | Aclaris Therapeutics | N/A | |
| MD DO | Aclaris Therapeutics | 54 | |
| Luciano Bonanni | Fonar | 69 | |
| Hugh Davis | Aclaris Therapeutics | 65 | |
| Samantha Kwok | Prenetics Global | N/A | |
| Toby Juvenal | Castle Biosciences | 63 | |
| Neal DO | Aclaris Therapeutics | 54 | |
| Olivier Jarry | DarioHealth Corp | 63 | |
Management Performance
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.32 |
Check Cap Leadership Team
Elected by the shareholders, the Check Cap's board of directors comprises two types of representatives: Check Cap inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Check. The board's role is to monitor Check Cap's management team and ensure that shareholders' interests are well served. Check Cap's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Check Cap's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Saar Levi, Interim Officer | ||
| Mira Rosenzweig, Executive Officer | ||
| David Benaim, Interim Officer | ||
| Joshua Belkar, Vice President - Operations | ||
| Alex Ovadia, CEO Director | ||
| Yoav Kimchy, Founder, CTO and Director | ||
| Noa MBA, Director Resources | ||
| Dan Hilerowitz, Chief Officer | ||
| Iris EvenTov, Interim Officer |
Check Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Check Cap a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.54 | ||||
| Return On Asset | -0.32 | ||||
| Current Valuation | (20.05 M) | ||||
| Shares Outstanding | 5.85 M | ||||
| Shares Owned By Insiders | 25.06 % | ||||
| Shares Owned By Institutions | 0.23 % | ||||
| Number Of Shares Shorted | 12.07 K | ||||
| Price To Earning | (2.47) X | ||||
| Price To Book | 0.20 X | ||||
| EBITDA | (17.65 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Check Cap. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. For more information on how to buy Check Stock please use our How to buy in Check Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Check Cap. If investors know Check will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Check Cap listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.00) | Return On Assets (0.32) | Return On Equity (0.54) |
The market value of Check Cap is measured differently than its book value, which is the value of Check that is recorded on the company's balance sheet. Investors also form their own opinion of Check Cap's value that differs from its market value or its book value, called intrinsic value, which is Check Cap's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Check Cap's market value can be influenced by many factors that don't directly affect Check Cap's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Check Cap's value and its price as these two are different measures arrived at by different means. Investors typically determine if Check Cap is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Check Cap's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.